Rico-Fontalvo, JorgeAroca-Martínez, GustavoDaza-Arnedo, RodrigoCabrales, JoséRodríguez-Yánez, TomásCardona-Blanco, MaríaMontejo-Hernández, JuanRodelo Barrios, DairoPatiño-Patiño, JhonnyOsorio Rodríguez, Elber2023-03-312023-03-312023Rico-Fontalvo, J.; Aroca-Martínez, G.; Daza-Arnedo, R.; Cabrales, J.; Rodríguez-Yanez, T.; Cardona-Blanco, M.; Montejo- Hernández, J.; Rodelo Barrios, D.; Patiño-Patiño, J.; Osorio Rodríguez, E. Novel Biomarkers of Diabetic Kidney Disease. Biomolecules 2023, 13, 633. https://doi.org/10.3390/ biom130406332218273Xhttps://hdl.handle.net/20.500.12442/12149Diabetic kidney disease (DKD) is a highly prevalent condition worldwide. It represents one of the most common complications arising from diabetes mellitus (DM) and is the leading cause of end-stage kidney disease (ESKD). Its development involves three fundamental components: the hemodynamic, metabolic, and inflammatory axes. Clinically, persistent albuminuria in association with a progressive decline in glomerular filtration rate (GFR) defines this disease. However, as these alterations are not specific to DKD, there is a need to discuss novel biomarkers arising from its pathogenesis which may aid in the diagnosis, follow-up, therapeutic response, and prognosis of the disease.pdfengAttribution-NonCommercial-NoDerivatives 4.0 InternacionalBiomarkersDiabetic kidney diseasePathogenesisDiabetes mellitusinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://doi.org/10.3390/biom13040633https://www.mdpi.com/2218-273X/13/4/633